Clinical trials: Empagliflozin
Type 2 Diabetes, Dyslipidemias
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
- Trial name
- NCT06578676
- Testing
- Empagliflozin 25 MG, Ezetimibe/Rosuvastatin 10/10mg, Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharm
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Healthy
Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 10773 administered to healthy Japanese male subjects with single rising oral doses (1, 5, 10, 25, and 100 mg).
- Trial name
- NCT02182453
- Testing
- BI 10773 - single rising dose
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
Primary objective: safety and tolerability of BI 10773 in male and female patients with type 2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773
- Trial name
- NCT00558571
- Testing
- BI 10773 low dose, BI 10773 medium dose, BI 10773 high dose
- Where
- 3 sites in Germany
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
Randomized, Single Oral Dose, Two-period, Two Sequence, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin-Linagliptin-Metformin XR Tablet 25mg/ 5mg/1000mg (25mg Empagliflozin /5mg Linagliptin /1000mgMetformin…
- Trial name
- NCT07213895
- Testing
- Empagliflozin/Linagliptin/Metformin HCL, Trijardy® XR Extended release film coated tablets
- Where
- Jordan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Healthy
Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers
The objective of the study is to investigate the relative bioavailability of the final tablet formulation (FF) of BI 10773 in comparison to the tablet formulation 2 (TF2).
- Trial name
- NCT01242176
- Testing
- BI 10773 XX (Trial Formulation 2), BI 10773 (Final Formulation)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers
Trial to assess the effect of food on the pharmacokinetics and the extent of absorption of a single dose BI 10773 tablet in healthy subjects
- Trial name
- NCT02172209
- Testing
- BI 10773
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Diabetes Mellitus, Type 2 DM
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management…
- Trial name
- GLYCO-3P (NCT06862739)
- Testing
- Empagliflozin+Linagliptin+Metformin
- Where
- 2 sites in Pakistan
- Volunteers
- 800 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Diabetes Mellitus
Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus
The main purpose of the VETA trial is to verify the potential beneficial effects of the combination of micronutrients namely Vitamin D3 and K2 in combination with oral antihyperglycemic Empagliflozin in Diabetes Mellitus
- Trial name
- VETA (NCT05417880)
- Testing
- Oral Hypoglycemic Agents,Oral, Voreta, Voreta plus SunnyD PRO
- Where
- Pakistan
- Volunteers
- 340 people
- Sponsor
- Scotmann Pharmaceuticals
Kidney Disease, Chronic
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.
- Trial name
- NCT06527846
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 1,024 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773 compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM with insufficient glycaemic control.
- Trial name
- NCT01177813
- Testing
- BI 10773, BI 10773 open label
- Where
- 124 sites in United States, Belgium and 7 more
- Volunteers
- 986 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus
- Trial name
- NCT02453555
- Testing
- Linagliptin, Empagliflozin + linagliptin low dose, Empagliflozin + linagliptin high dose
- Where
- 40 sites in Japan
- Volunteers
- 275 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
- Trial name
- NCT01289990
- Testing
- BI 10773, Sitagliptin 100mg
- Where
- 243 sites in United States, Belgium and 17 more
- Volunteers
- 2,705 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Comparative Effectiveness of Empagliflozin in the US
Empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, was launched as a treatment for type 2 diabetes mellitus (T2DM) in the U.S. in August 2014.
- Trial name
- NCT03363464
- Testing
- Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist
- Where
- United States
- Volunteers
- 230,000 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
gemigliptin,SGLT-2i DDI study
- Trial name
- NCT03565458
- Testing
- Gemigliptin, Dapagliflozin, Empagliflozin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diabetes Mellitus, Type 1
Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
This open-label study aims to evaluate the impact of BI 10773 treatment on glomerular filtration rate under controlled conditions of euglycaemia and hyperglycaemia in subjects with type 1 diabetes mellitus with or without renal…
- Trial name
- NCT01392560
- Testing
- BI 10773
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Insulin Resistance - Type A, Insulin Resistance - Type B
A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )
A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-02 (NCT04221152)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim